Strong growth and deleveraging support raised guidance, but IRA headwinds remain a material pharmacy overhang.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-07-31 |
| Length | 60 minutes |
| EPS | $0.45 |
| EPS consensus | $0.37 |
| Revenue | $3.9B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25 · Q2 FY25
All BTSG earnings · Back to BTSG overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.